Arabic Arabic English English French French German German
dark

Study suggests adding drug berzosertib to standard treatment for metastatic bladder cancer does not benefit patients

A Phase 2 trial led by City of Hope, a world-renowned research and treatment center for cancer and diabetes, suggests that adding the novel ataxia telangiectasia and Rad3-related (ATR) inhibitor drug berzosertib to standard-of-care chemotherapy for patients with metastatic urothelial cancer does not extend progression-free survival. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

Stem cells model genetic risk for developing Alzheimer’s disease

Next Post

One in three Americans had COVID-19 by the end of 2020

Related Posts
Total
0
Share